Search
forResearch 10 of 1000+
- Generic competition and pharma patent strategies - a sequel
- The Pharma Market as Reflected by Patents
- Abstracts of the Final Year Projects of Pharm D Clinical Pharmacy Students Faculty of Pharmacy Beni-suef University Year 2024/2025
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- 16．微生物学研究室
- Anti-Müllerian hormone confirms the novel classification of female functional androgenization including polycystic ovary syndrome
- Back cover
- Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions, 1–30 September 2016
- Industry updates from the field of stem cell research and regenerative medicine in June 2019
Community 10 of 25
- Clascoterone won't be available until q4 2027 at the earliest per the newest Cosmo Pharma newsletter
- Everything you ever wanted to know about Pelage Pharma's PP405: how it works and what to expect
- Breezula Phase III 12-Month Data Released by Cosmo Pharma
- Is this legit oral minoxidil from Healing Pharma ?
- Cosmo Pharma 2025 Investor Day Report
- Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025
- Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
- Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
- Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
- Finally - Big Pharma now targeting hair-loss once again!
Learn
— no results
Try a deeper search in learn →